Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
European operations' revenue grew 58.4% to Rs 599.7 crore
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The IPO comprises a fresh issue of up to Rs. 11,600 million and an offer for sale of up to 7,305,245 equity shares of Rs. 2 each of Glenmark Life Sciences by Glenmark Pharmaceuticals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)